Aura Biosciences (AURA) Net Cash Flow (2020 - 2026)

Aura Biosciences has reported Net Cash Flow for 7 years, with the latest figure at $25.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 286.1% year-over-year to $25.3 million; the trailing twelve-month figure through Mar 2026 stood at $46.8 million (up 290.7% YoY), and the FY2025 full-year result was $28.0 million, up 398.31% from the prior year.
• Net Cash Flow for Q1 2026 stood at $25.3 million, up from $12.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $69.1 million in Q2 2025, with the low at -$83.1 million in Q1 2023.
• Historically, Net Cash Flow has averaged -$3.7 million across 5 years, with a median of $6.3 million in 2024.
• The largest YoY upside for Net Cash Flow was 1721.18% in 2025 against a maximum downside of 1181.06% in 2025.
• Aura Biosciences' Net Cash Flow stood at $60.3 million in 2022, then sank by 124.08% to -$14.5 million in 2023, then soared by 143.29% to $6.3 million in 2024, then jumped by 92.84% to $12.1 million in 2025, then surged by 108.75% to $25.3 million in 2026.
• The last three Net Cash Flow figures came in at $25.3 million (Q1 2026), $12.1 million (Q4 2025), and -$59.8 million (Q3 2025), per Business Quant data.